Skip to main navigation Skip to search Skip to main content

Primary Thrombotic Microangiopathy in Pediatric Patients

  • Andrés David Aranzazu Ceballos
  • , Lina María Martínez Sánchez
  • , Ana Paulina Pamplona Sierra
  • , Daniela Vergara Yánez
  • , Liliana Franco Hincapié
  • , Richard Baquero Rodriguez

Research output: Contribution to scientific journalArticle in an indexed scientific journalpeer-review

Abstract

Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.
Original languageUndefined/Unknown
JournalGlobal Pediatric Health
Volume11
DOIs
StatePublished - Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Types Minciencias

  • Artículos de investigación con calidad A2 / Q2

Cite this